CALCIUM

US Approved OTC

First marketed in 1921

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	Ca
Molecular Weight	40.078
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Ca]

InChI

InChIKey=FAQLAUHZSGTTLN-UHFFFAOYSA-N

InChI=1S/Ca.2H

HIDE SMILES / InChI

Molecular Formula	Ca
Molecular Weight	40.078
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.globalrph.com/calcium_supplements.htm | https://www.ncbi.nlm.nih.gov/pubmed/26265479http://apps.who.int/iris/bitstream/10665/43579/1/9789241530729_eng.pdfhttps://www.drugs.com/inactive/calcium-phosphate-dibasic-anhydrous-463.html
Curator's Comment: description was created based on several sources, including https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260884.htm | http://www.webmd.com/drugs/2/drug-159847/calcium-phosphate-dibasic-oral/details

Anhydrous dibasic calcium phosphate is a calcium salt of phosphoric acid. It is used as a diluent in pharmaceutical industry, in some toothpastes as a polishing agent. Calcium phosphate is generally recognized as safe by FDA. Dibasic calcium phosphate is ised as a supplement to treat conditions associated with calcium deficit, such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany)

Originator

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2578
Hypocalcemia 75 Sources: http://www.globalrph.com/calcium_supplements.htm	Primary	Not Provided 504	Unknown Approved Use Unknown
Chronic obstructive pulmonary disease 174 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26265479	Palliative	Phase I 428	Unknown Approved Use Unknown
Cystic fibrosis 120 Sources: https://clinicaltrials.gov/ct2/show/NCT01543191	Palliative	Phase I 428	Unknown Approved Use Unknown
Unknown 2578
Hypocalcemia 75 Sources: https://www.drugs.com/mmx/calcium-phosphate-dibasic.html	Primary	Approved 8429	Unknown Approved Use Hypocalcemia, chronic (treatment) — Oral calcium supplements provide a source of calcium ion for treating calcium depletion occurring in conditions such as chronic hypoparathyroidism, pseudohypoparathyroidism, osteomalacia, rickets, chronic renal failure, and hypocalcemia secondary to the administration of anticonvulsant medications. When chronic hypocalcemia is due to vitamin D deficiency, oral calcium salts may be administered concomitantly with vitamin D analogs. However, calcium phosphate should not be used in patients with hypoparathyroidism or renal failure, since phosphate levels may be too high and giving more phosphate would exacerbate the condition. Calcium supplements should not be used in hyperparathyroidism, unless the need for a calcium supplement is high and the patient is carefully monitored. For treatment of hypocalcemia, supplementation is preferred

PubMed

Title	Date	PubMed
Studies on the calcemic effect of intravenous secretin in humans.	1975 Jun	1220513
Ca2+-induced contraction of cat esophageal circular smooth muscle cells.	2001 Apr	11245615
Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity.	2001 Apr 27	11278295
Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations.	2001 Apr 7	11298490
Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity.	2001 Aug 28	11513607
Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds.	2001 Dec 21	11592964
Complement activation in factor D-deficient mice.	2001 Dec 4	11724962
Functional expression and characterization of a voltage-gated CaV1.3 (alpha1D) calcium channel subunit from an insulin-secreting cell line.	2001 Jul	11435619
Aluminum toxicity alters the regulation of calbindin-D28k protein and mRNA expression in chick intestine.	2001 Jul	11435522
Analysis of the native quaternary structure of vanilloid receptor 1.	2001 Jul 27	11358970
Mechanisms of regulation of agonist efficacy at the 5-HT(1A) receptor by phospholipid-derived signaling components.	2001 Jun	11356925
Vasopressin-stimulated Ca2+ spiking in vascular smooth muscle cells involves phospholipase D.	2001 Jun	11356622
Long-term alteration of calcium homeostatic mechanisms in the pilocarpine model of temporal lobe epilepsy.	2001 Jun 8	11382382
RGS4 inhibits platelet-activating factor receptor phosphorylation and cellular responses.	2001 Mar 27	11297424
Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities.	2001 Nov	11701772
Activating mutations of the calcium-sensing receptor: management of hypocalcemia.	2001 Nov	11701698
Regression of ventral striatum hypometabolism after calcium/calcitriol therapy in paroxysmal kinesigenic choreoathetosis due to idiopathic primary hypoparathyroidism.	2001 Nov	11606688
Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors.	2001 Nov 1	11705452
Hypoxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis.	2001 Nov 30	11577072
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.	2001 Oct	11606325
Familial intrahepatic cholestasis 1: studies of localization and function.	2001 Oct	11584374
Microarray analysis of differential gene expression in lead-exposed astrocytes.	2001 Oct 1	11578147
Phosphoinositide 3-kinase isoforms selectively couple receptors to vascular L-type Ca(2+) channels.	2001 Oct 12	11597992
Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart.	2001 Oct 26	11679415
Regional differences in functional receptor distribution and calcium mobilization in the intact human lens.	2001 Sep	11527950
Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism.	2001 Sep	11500311
Heterologous expression of the Na(+),K(+)-ATPase gamma subunit in Xenopus oocytes induces an endogenous, voltage-gated large diameter pore.	2001 Sep 1	11533133
Ameliorative effect of vasopressin-(4-9) through vasopressin V(1A) receptor on scopolamine-induced impairments of rat spatial memory in the eight-arm radial maze.	2001 Sep 7	11553362
Cannabinoids attenuate depolarization-dependent Ca2+ influx in intermediate-size primary afferent neurons of adult rats.	2002	12421626
The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells.	2002 Apr 19	11830588
Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells.	2002 Dec	12456425
CXCR4 expression on monocytes is up-regulated by dexamethasone and is modulated by autologous CD3+ T cells.	2002 Feb	11872090
Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene.	2002 Feb	11796525
Characterization of basolateral K+ channels underlying anion secretion in the human airway cell line Calu-3.	2002 Feb 1	11826162
Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice.	2002 Jan 15	11809688
Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones.	2002 Jul	12110441
Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.	2002 Jul	12101159
Transcriptional induction of CYP1A1 by oltipraz in human Caco-2 cells is aryl hydrocarbon receptor- and calcium-dependent.	2002 Jul 5	11959854
Human kidney diamine oxidase: heterologous expression, purification, and characterization.	2002 Jun	12072962
Expression of functional CCR and CXCR chemokine receptors in podocytes.	2002 Jun 15	12055238
Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor.	2002 Mar	11895442
Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart.	2002 Mar	11856964
Alpha(1H) mRNA in single skeletal muscle fibres accounts for T-type calcium current transient expression during fetal development in mice.	2002 Mar 15	11897840
Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products.	2002 May 15	11988098
Neuronal apoptosis inhibitory protein: Structural requirements for hippocalcin binding and effects on survival of NGF-dependent sympathetic neurons.	2002 Nov 4	12445469
Molecular cloning and characterization of the human voltage-gated calcium channel alpha(2)delta-4 subunit.	2002 Sep	12181424
Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors.	2002 Sep 15	12069687
Effects of endothelin B receptor agonists on amyloid beta protein (25-35)-induced neuronal cell death.	2002 Sep 6	12383957
A critical interplay between Ca2+ inhibition and activation by Mg2+ of AC5 revealed by mutants and chimeric constructs.	2002 Sep 6	12065575
Mechanism of enhanced calcium sensitivity and alpha 2-AR vasoreactivity in chronic NOS inhibition hypertension.	2003 Jan	12388232

Patents

Sample Use Guides

In Vivo Use Guide

oral: 500 to 2000 mg elemental calcium a day, in divided doses (bid-qid). inhalation: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (calcium lactate inhalation powder (CLIP) formulation) (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure.

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:55:06 GMT 2023` Edited by `admin` on `Fri Dec 15 15:55:06 GMT 2023`
Record UNII	SY7Q814VUP
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CALCIUM

Systematic Name

English

CALCIUM [ORANGE BOOK]

Common Name

English

Calcium [WHO-DD]

Common Name

English

CALCIUM [VANDF]

Common Name

English

CALCIUM [USP-RS]

Common Name

English

CALCIUM [MI]

Common Name

English

CALCIUM [HSDB]

Common Name

English

CALCIUM [II]

Common Name

English

Classification Tree Code System Code

LOINC

42857-3